Drugs / Monlunabant
Monlunabant
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06542536 | Aug → Oct 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT05891834 | Sep 2023 → Jun 2024 | abdominal obesity-metabolic syndrome, obesity disorder | Inversago Pharma Inc. | Completed | Met primary |
| Phase 2 | NCT05514548 | Oct 2022 → Aug 2024 | diabetic kidney disease | Inversago Pharma Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-20 | Novo Nordisk A/S | Results Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed novonordisk.com ↗
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-20 | Novo Nordisk A/S | Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed novonordisk.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | monlunabant | “we investigated the efficacy and safety of monlunabant, a second-generation cannabinoid receptor 1 inverse agonist, in individuals with DKD.” PMID 41866124 ↗ Mar 20262“BACKGROUND: Monlunabant, a novel cannabinoid receptor 1 (CB1R) inverse agonist, has shown encouraging weight loss efficacy and tolerability.” PMID 41038215 ↗ Sep 2025 |
| Known as | MRI-1891 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314529 ↗ |
| Known as | MRI-1891, (S)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314529 ↗ |
| Action | Inhibit | “CB1R inverse agonist” PMID 41038215 ↗ Sep 2025 |
| Modality | Small molecule | — CHEMBL5314529 ↗ |
| Route | Oral | “Participants were randomized (1:1:1) to receive oral tablets of monlunabant 10 mg or 25 mg, or placebo once daily for 16 weeks.” PMID 41866124 ↗ Mar 2026 |